.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,949,571

« Back to Dashboard

Claims for Patent: 6,949,571

Title: 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Abstract:The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. ##STR1## In the formula, Q indicates NH, O or S; and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group or a group represented by the formula --X-A (wherein X indicates a single bond, an optionally substituted C.sub.1-6 alkylene group etc.; and A indicates an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
Inventor(s): Nagato; Satoshi (Chiba, JP), Ueno; Kohshi (Ibaraki, JP), Kawano; Koki (Ibaraki, JP), Norimine; Yoshihiko (Ibaraki, JP), Ito; Koichi (Chiba, JP), Hanada; Takahisa (Ibaraki, JP), Ueno; Masataka (Ibaraki, JP), Amino; Hiroyuki (Ibaraki, JP), Ogo; Makoto (Ibaraki, JP), Hatakeyama; Shinji (Ibaraki, JP), Groom; Anthony John (Wiltshire, GB), Rivers; Leanne (Kent, GB), Smith; Terence (Cambridgeshire, GB)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:10/296,719
Patent Claims: 1. A compound represented by the following formula, a salt thereof or a hydrate thereof, ##STR1319##

wherein Q indicates O, R.sup.3 and R.sup.5 are the same as or different from each other and each indicates a hydrogen atom or a C.sub.1-6 alkyl group; and R.sup.1 indicates a C.sub.3-8 cycloalkyl group, a 5 to 14 membered non-aromatic heterocyclic group, a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5 to 14 membered aromatic heterocyclic group, which may be substituted, respectively, and R.sup.2 and R.sup.4 are the same as or different from each other and each indicates a group represented by the formula --X-A wherein X indicates a single bond and A indicates a C.sub.3-6 cycloalkyl group, a 5 to 14 membered non-aromatic heterocyclic group, a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5 to 14 membered aromatic heterocyclic group, which may be substituted, respectively.

2. The compound according to claim 1, a salt thereof or a hydrate thereof, which is represented by the formula: ##STR1320##

wherein Q indicates O; X.sup.1 is a single bond and X.sup.2 and X.sup.3 are each a single bond and A.sup.1, A.sup.2 and A.sup.3 are the same as or different from each other and each indicates an optionally substituted C.sub.3-8 cycloalkyl group, an optionally substituted 5 to 14-membered non-aromatic heterocyclic group, an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or an optionally substituted 5 to 14-membered aromatic heterocyclic group; and R.sup.17 indicates a hydrogen atom or a C.sub.1-6 alkyl group and R.sup.18 indicates a hydrogen atom.

3. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein X.sup.1 is a single bond and X.sup.2 and X.sup.3 are each a single bond and A.sup.1, A.sup.2 and A.sup.3 are a C.sub.3-8 cycloalkyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C.sub.6-14 aromatic hydrocarbocyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be optionally substituted with one or more groups selected from the following substituent group b: the group consisting of (1) hydroxy group, (2) a halogen atom, (3) nitrile group, (4) nitro group, (5) a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group or a C.sub.2-6 alkynyl group which may be optionally substituted respectively with one or more groups selected from the group consisting of hydroxy group, nitrile group, a halogen atom, a C.sub.1-6 alkylamino group, a di-(C.sub.1-6 alkyl)amino group, a C.sub.2-6 alkenylamino group, a di(C.sub.2-6 alkenylamino) group, a C.sub.2-6 alkynylamino group, a di(C.sub.2-6 alkynylamino) group, an N-C.sub.1-6 alkyl-N-C.sub.2-6 alkenylamino group, an N-C.sub.1-6 alkyl-N-C.sub.2-6 alkynylamino group, an N-C.sub.2-6 alkenyl-N-C.sub.2-6 alkynylamino group, an aralkyloxy group, a TBDMS oxy group, a C.sub.1-6 alkylsulfonylamino group, a C.sub.1-6 alkylcarbonyloxy group, a C.sub.2-6 alkenylcarbonyloxy group, a C.sub.2-6 alkynylcarbonyloxy group, an N-C.sub.1-6 alkylcarbamoyl group, an N-C.sub.2-6 alkenylcarbamoyl group and an N-C.sub.1-6 alkynylcarbamoyl group, (6) a C.sub.1-6 alkoxy group, a C.sub.2-6 alkenyloxy group or a C.sub.2-6 alkynyloxy group which may be optionally substituted respectively with one or more groups selected from the group consisting of a C.sub.1-6 alkylamino group, an aralkyloxy group and hydroxy group, (7) a C.sub.1-6 alkylthio group, a C.sub.2-6 alkenylthio group or a C.sub.2-6 alkynylthio group which may be optionally substituted respectively with one or more groups selected from the group consisting of hydroxy group, nitrile group, a halogen atom, a C.sub.1-6 alkylamino group, an aralkyloxy group, a TBDMS oxy group, a C.sub.1-6 alkylsulfonylamino group, a C.sub.1-6 alkylcarbonyloxy group and a C.sub.1-6 alkylcarbamoyl group, (8) a carbonyl group substituted with a group selected from the group consisting of a C.sub.1-6 alkoxy group, amino group, a C.sub.1-6 alkylamino group, a di(C.sub.1-6 alkyl)amino group, a C.sub.2-6 alkenylamino group, a di(C.sub.2-6 alkenyl)amino group, a C.sub.2-6 alkynylamino group, a di(C.sub.2-6 alkynyl)amino group, an N-C.sub.1-6 alkyl-N-C.sub.2-6 alkenylamino group, an N-C.sub.1-6 alkyl-N-C.sub.2-6 alkynylamino group and an N-C.sub.2-6 alkenyl-N-C.sub.2-6 alkynylamino group, (9) amino group which may be optionally substituted with one or two groups selected from the group consisting of a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkylsulfonyl group, a C.sub.2-6 alkenylsulfonyl group, a C.sub.2-6 alkynylsulfonyl group, a C.sub.1-6 alkylcarbonyl group, a C.sub.2-6 alkenylcarbonyl group and a C.sub.2-6 alkynylcarbonyl group, (10) a C.sub.1-6 alkylsulfonyl group, (11) a C.sub.2-6 alkenylsulfonyl group, (12) a C.sub.2-6 alkynylsulfonyl group, (13) a C.sub.1-6 alkylsulfinyl group, (14) a C.sub.2-6 alkenylsulfinyl group, (15) a C.sub.2-6 alkynylsulfinyl group, (16) a formyl group, (17) a C.sub.3-8 cycloalkyl group or a C.sub.3-8 cycloalkenyl group which may be optionally substituted respectively with one or more groups selected from the group consisting of hydroxy group, a halogen atom, nitrile group, a C.sub.1-6 alkyl group, a C.sub.1-6 alkyloxy group, a C.sub.1-6 alkyloxy C.sub.1-6 alkyl group and an aralkyl group, (18) a 5- to 14-membered non-aromatic heterocyclic group which may be optionally substituted with one or more groups selected from the group consisting of hydroxy group, a halogen atom, nitrile group, a C.sub.1-6 alkyl group, a C.sub.1-6 alkyloxy group, a C.sub.1-6 alkyloxy C.sub.1-6 alkyl group and an aralkyl group, (19) a C.sub.6-14 aromatic hydrocarbocyclic group which may be optionally substituted with one or more groups selected from the group consisting of hydroxy group, a halogen atom, nitrile group, a C.sub.1-6 alkyl group, a C.sub.1-6 alkyloxy group, a C.sub.1-6 alkyloxy C.sub.1-6 alkyl group and an aralkyl group, and (20) a 5- to 14-membered aromatic heterocyclic group which may be optionally substituted with one or more groups selected from the group consisting of hydroxy group, a halogen atom, nitrile group, a C.sub.1-6 alkyl group, a C.sub.1-6 alkyloxy group, a C.sub.1-6 alkyloxy C.sub.1-6 alkyl group and an aralkyl group.

4. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein A.sup.1, A.sup.2 and A.sup.3 are the same as or different from each other and each represents phenyl group, pyrrolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, thienyl group, thiazolyl group, furyl group, naphthyl group, quinolyl group, iso-quinolyl group, indolyl group, benzimidazolyl group, benzothiazolyl group, benzoxazolyl group, imidazopyridyl group, carbazolyl group, cyclopentyl group, cyclohexyl group, cyclohexenyl group, dioxinyl group, adamantyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group or morpholyl group which may optionally have a substituent, respectively.

5. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein A.sup.1, A.sup.2 and A.sup.3 are the same as or different from each other and each is a group represented by the formula: ##STR1321##

which may be substituted.

6. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein A.sup.1, A.sup.2 and A.sup.3 are the same as or different from each other and each is optionally substituted with hydroxyl group, a halogen atom, amino group or nitrile group.

7. The compound according to claim 5, a salt thereof or a hydrate thereof, wherein the substituents of A.sup.1, A.sup.2 and A.sup.3 are the same as or different from each other and each is hydroxyl group, a halogen atom or, amino group, nitrile group or nitro group.

8. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein R.sup.17 and R.sup.18 represent hydrogen atom.

9. The compound according to claim 2, a salt thereof or a hydrate thereof, wherein the bonding site of the substituent at A.sup.1, A.sup.2 and/or A.sup.3 are .alpha.-position of the carbon atom bonding to the group X.sup.1, X.sup.2 and X.sup.3, respectively.

10. The compound according to claim 1, a salt thereof or a hydrate thereof, which is a compound selected from: 3-(2-cyanophenyl)-5-(2-methylsulfonylaminophenyl)-1-phenyl-1,2-dihydropyri din-2-one; 3-(2-chloro-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-nitrophenyl)-1,2-dihydropyridin-2-one ; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-aminophenyl)-1,2-dihydropyridin-2-one ; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methylsulfonylaminophenyl)-1,2-dihydr opyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methylaminophenyl)-1,2-dihydropyridin -2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-dimethylaminophenyl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-[3-(5-methoxymethyl-2-oxazolidinon-3-yl) -phenyl]-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methoxycarbonylphenyl)-1,2-dihydropyr idin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methylaminocarbonylphenyl)-1,2-dihydr opyridin-2-one; 3-(2-cyano-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(4-hydroxyphenyl)-1,2-dihydropyridin-2- one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(4-dimethylaminoethoxyphenyl)-1,2-dihyd ropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-formylphenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-hydroxymethylphenyl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-cyanomethylphenyl)-1,2-dihydropyridin e-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-acetylaminomethylphenyl)-1,2-dihydrop yridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methylsulfonylaminomethylphenyl)-1,2- dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-acetoxymethylphenyl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-methylthiophenyl)-1,2-dihydropyridin- 2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-methylsulfonylphenyl)-1,2-dihydropyri din-2-one; 3-(2-cyanophenyl)-5-(2-formylthiophen-3-yl)-1-phenyl-1,2-dihydropyridin-2- one; 3-(2-cyanophenyl)-5-(2-diethylaminomethylthiophen-3-yl)-1-phenyl-1,2-dihyd ropyridin-2-one; 3-(2-cyanophenyl)-5-(2-hydroxymethylthiophen-3-yl)-1-phenyl-1,2-dihydropyr idine-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-benzyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-phenyl-(2-pyridyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-diphenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(3,4-dimethoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(thiophen-3-yl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-fluorophenyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(thiophen-2-yl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(3-furfuryl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-furfuryl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-methoxycarbonylphenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-on e; 3-phenyl-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-fluorophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-methoxyphenyl)-1,2-dihydropyridin-2- one; 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(4-methoxy-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-(3-methoxyphenyl)-1,2-dihydropyridi n-2-one; 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-(3-fluorophenyl)-1,2-dihydropyridin -2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-fluorophenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-fluorophenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-methoxyphenyl)-1,2-dihydropyridin-2-o ne; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methoxyphenyl)-1,2-dihydropyridin-2-o ne; 3-phenyl-5-(2-pyridyl)-1-(3-fluorophenyl)-1,2-dihydropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-fluorophenyl)-1,2-dihydropyridin-2-o ne; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-formylphenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-formylphenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-chlorophenyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-tolyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-trifluoromethylphenyl)-1,2-dihydropyr idin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(thiophen-3-yl)-1,2-dihydropyridin-2-one ; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-furfuryl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-tolyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-trifluoromethylphenyl)-1,2-dihydropyr idin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-methoxypyridin-5-yl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(pyrimidin-5-yl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-benzyloxymethylpyridin-5-yl)-1,2-dihy dropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-ethylthiopyridin-5-yl)-1,2-dihydropyr idin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-pyridyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-methoxypyridin-5-yl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-chloropyridin-5-yl)-1,2-dihydropyridi n-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-fluoropyridin-5-yl)-1,2-dihydropyridi n-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-methoxyphenyl)-1,2-dihydropyridin-2-o ne; 3-phenyl-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one; 3-(thiophen-3-yl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2one; 3-(2,6-dimethylphenyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanothiophen-3-yl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2- one; 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-on e; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-hydroxyphenyl)-1,2-dihydropyridin-2- one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-dimethylaminoethoxyphenyl)-1,2-dihyd ropyridin-2-one; 3-(2-chlorophenyl)-5-(2-pyridyl)-1-(3-dimethylaminopropoxyphenyl)-1,2-dihy dropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-hydroxymethylphenyl)-1,2-dihydropyrid in-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(4-cyanomethylphenyl)-1,2-dihydropyridin -2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-cyanomethylphenyl)-1,2-dihydropyridin -2-one; 3-(2-cyanophenyl)-5-(6-diethylaminomethyl-2-pyridyl)-1-phenyl-1,2-dihydrop yridin-2-one; 3-(2-cyanophenyl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one; 3-(2-hydroxypyridin-6-yl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2one: 1-(2-aminobenzothiazol-6-yl)-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropy ridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(1-benzyl-1,2,3,6-tetrahydropyridin-5-yl )-1,2-dihydropyridin-2-one; 3-[2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-phenyl-5-(2-pyridyl)-1,2-dih ydropyridin-2-one; 3-(2-cyanophenyl)-5-(6-methylpyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-o ne; 3-(2-cyanophenyl)-5-(5-methylpyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2-o ne; 3-(2-cyanophenyl)-5-(3-hydroxypyridin-2-yl)-1-phenyl-1,2-dihydropyridin-2- one; 3-(2-cyanophenyl)-1-phenyl-5-(2-thiazolyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-methoxypyridin-6-yl)-1-phenyl-1,2-dihydropyridin-2- one; 1-(4-aminophenyl)-3-(2-cyanophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one ; 1-(3-aminophenyl)-3-(2-cyanophenyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2 -one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-aminotoluen-4-yl)-1,2-dihydropyridin- 2-one; 3-(2-cyanophenyl)-1-[3-(dimethylaminoethoxy)phenyl]-5-(2-pyridyl)-1,2-dihy dropyridin-2-one; 3-(2-cyanophenyl)-1-[3-(piperidinoethoxy)phenyl]-5-(2-pyridyl)-1,2-dihydro pyridin-2-one; 3-(2-cyanophenyl)-1-[3-(pyrrolidinoethoxy)phenyl]-5-(2-pyridyl)-1,2-dihydr opyridin-2-one; 3-(2-cyanophenyl)-1-[3-(diisoproylaminoethoxy)phenyl]-5-(2-pyridyl)-1,2-di hydropyridin-2-one; 3-(2-cyanophenyl)-1-[3-(4-piperidinobutoxy)phenyl]-5-(2-pyridyl)-1,2-dihyd ropyridin-2-one; 3-(2-cyanophenyl)-1-(4-nitrophenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-one ; 1-phenyl-5-(2-pyridyl)-3-(2-thiazolyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-1-(3-pyridyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one ; 3-(2-fluoropyridin-3-yl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-o ne; 3-(2-cyanopyridin-3-yl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-1-(3-nitrophenyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2 -one; 3-(2-nitrophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one; 3-(2-formylthiophen-3-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-naphthyl)-1,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(1-naphthyl)-1,2-dihydropyridin-2-one; 5-(2-aminopyridin-6-yl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-on e; 5-(2-bromopyridin-6-yl)-3-(2-cyanophenyl)-1-phenyl-1,2-dihydropyridin-2-on e; 3-(2-cyanophenyl)-5-(2-morphorinopyridin-6-yl)-1-phenyl-1,2-dihydropyridin -2-one; 3-(2-cyanophenyl)-1-(3-hydroxyphenyl)-5-(2-pyridyl)-1,2-dihydropyridin-2-o ne; 3-(2-cyanophenyl)-1-[3-(4-piperidyloxy)]phenyl-5-(2-pyridyl)-1,2-dihydropy ridin-2-one; 1-[3-(N-acetylpiperidin-4-yl-oxy)phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1 ,2-dihydropyridin-2-one; 3-(2-cyanophenyl)-1-{3-[1-(methanesufonyl)piperidin-4-yl-oxy]phenyl}-5-(2- pyridyl)-1,2-dihydropyridin-2-one; 1-[3-(N-methylpiperidin-4-yl-oxy)phenyl]-3-(2-cyanophenyl)-5-(2-pyridyl)-1 ,2-dihydropyridin-2-one; 3-(6-chloro-1H-benzimidazol-2-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridi n-2-one; 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(2-nitrotoluen-4-yl)-1,2-dihydropyridin- 2-one; 3-(2-cyanothiophen-3-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one; 3-[2-(5-oxazolyl)phenyl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one; 3-[2-(5-oxazolyl)thiophen-3-yl]-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin- 2-one; and 3-[(2-ethoxycarbonylvinylthiophen-3-yl)-5-(2-pyridyl)-1-phenyl-1,2-dihydro pyridin-2-one.

11. A compound represented by the following formula, a salt thereof, or a hydrate thereof, ##STR1322##

wherein Q indicates O, R.sup.3 and R.sup.5 are the same as or different from each other and each indicates a hydrogen atom or a C.sub.1-6 alkyl group; R.sup.1 is a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5- to 14-membered aromatic heterocyclic group, which may be substituted, respectively, and R.sup.2 and R.sup.4 are the same as or different from each other and each indicates a group represented by the formula --X-A wherein X indicates a single bond and A indicates a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5 to 14 membered aromatic heterocyclic group, which may be substituted, respectively.

12. The compound of claim 11, which is 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, or a salt or hydrate thereof.

13. The compound of claim 11, which is 3-(2-cyanophenyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-one, or a salt or hydrate thereof.

14. The compound of claim 11, which is 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, or a salt or hydrate thereof.

15. The compound of claim 11, which is 3-(2-fluoro-3-pyridyl)-5-(2-pyridyl)-1-(3-pyridyl)-1,2-dihydropyridin-2-on e, or a salt or hydrate thereof.

16. The compound of claim 11, which is 3-(2-cyanophenyl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one, or a salt or hydrate thereof.

17. The compound of claim 11, which is 3-(2-cyanophenyl)-1-(3-pyridyl)-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-one , or a salt or hydrate thereof.

18. The compound of claim 11, which is 3-(2-fluoropyridin-3-yl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-o ne, or a salt or hydrate thereof.

19. The compound of claim 11, which is 3-(2-cyanopyridin-3-yl)-1-phenyl-5-(2-pyrimidinyl)-1,2-dihydropyridin-2-on e, or a salt or hydrate thereof.

20. A pharmaceutical composition which is an inhibitor to an .alpha.-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor and/or a kainate receptor, said composition comprising a compound represented by formula (I) as it is defined in claim 1, a salt thereof or a hydrate thereof, in an effective amount for the treatment of epilepsy, Parkinson's disease, Parkinson's syndrome, or multiple sclerosis, and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition according to claim 20, wherein it is an inhibitor to an AMPA receptor.

22. The pharmaceutical composition according to claim 20, wherein it is an inhibitor to a kainate receptor.

23. The pharmaceutical composition according to claim 20, which is a therapeutic agent for the diseases in which an AMPA receptor or a kainate receptor is participated.

24. The pharmaceutical composition according to claim 20, which is a therapeutic agent for the diseases in which a kainate receptor is participated.

25. The pharmaceutical composition according to claim 20, which is a therapeutic agent for Parkinson's disease.

26. The pharmaceutical composition according to claim 20, which is an agent for treating epilepsy or Parkinson's.

27. The pharmaceutical composition according to claim 20, which is an agent for treating multiple sclerosis.

28. A pharmaceutical composition which is an inhibitor to an .alpha.-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor and/or a kainate receptor, said composition comprising a compound represented by the following formula, a salt thereof or a hydrate thereof, ##STR1323##

wherein Q indicates O, R.sup.3 and R.sup.5 are the same as or different from each other and each indicates a hydrogen atom or a C.sub.1-6 alkyl group; R.sup.1 is a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5- to 14-membered aromatic heterocyclic group, which may be substituted, respectively, and R.sup.2 and R.sup.4 are the same as or different from each other and each indicates a group represented by the formula --X-A wherein X indicates a single bond and A indicates a C.sub.6-14 aromatic hydrocarbocyclic group, or a 5 to 14 membered aromatic heterocyclic group, which may be substituted, respectively, in an effective amount for the treatment of epilepsy, Parkinson's disease, Parkinson's syndrome, or multiple sclerosis, and a pharmaceutically acceptable carrier.

29. A method for treating a disease in which an AMPA receptor or a kainate receptor participates, by dosing to a patient, a pharmacologically effective dose of a compound represented by formula (I) as it is defined in claim 1 or any of claims 11 to 19, a salt thereof, or a hydrate thereof, wherein the disease is selected from the group consisting of Parkinson's disease epilepsy, Parkinson's syndrome, and multiple sclerosis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc